Product Description
Vertex is developing VX-121 as a treatment for cystic fibrosis. (Sourced from: https://investors.vrtx.com/news-releases/news-release-details/vertex-initiate-phase-3-development-program-new-once-daily)
Mechanisms of Action: CFTR Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Vertex
Company Location: BOSTON MA 02210
Company CEO: Reshma Kewalramani
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Belgium, Canada, Czech Republic, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Netherlands, New Zealand, Norway, Poland, Portugal, Spain, Sweden, Switzerland, United Kingdom, United States
Active Clinical Trial Count: 17
Highest Development Phases
Phase 3: Cystic Fibrosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| VX22-121-106 | P3 |
Enrolling by invitation |
Cystic Fibrosis |
2030-10-01 |
41% |
| VX22-121-106 | P3 |
Enrolling by invitation |
Cystic Fibrosis |
2030-10-01 |
41% |
| VX22-121-106 | P3 |
Enrolling by invitation |
Cystic Fibrosis |
2030-10-01 |
41% |
| VX21-121-105 | P3 |
Recruiting |
Cystic Fibrosis |
2030-06-30 |
|
| VX21-121-105 | P3 |
Unknown Status |
Cystic Fibrosis |
2027-08-02 |
|
| VX20-121-104 | P3 |
Unknown Status |
Cystic Fibrosis |
2027-04-16 |